Merck & Co., Inc. (MRK)[Tv]

Key Developments

• Phase 3 INTerpath-001 trial success for intismeran autogene + Keytruda in high-risk melanoma – This landmark result marked the first-ever statistically significant improvement in recurrence-free and distant-metastasis-free survival for an individualized mRNA cancer vaccine, validating Merck’s next-generation immuno-oncology platform and triggering a $43 billion market surge in a single day.
• FDA approval of Padcev (Pfizer/Astellas) + Keytruda for muscle-invasive bladder cancer regardless of cisplatin eligibility – Backed by 35% reduction in mortality risk, this approval significantly expands Keytruda’s addressable population and reinforces Merck’s dominance in combination immunotherapy.
• Positive Phase 3 results for Tulisokibart (MK-7240) in ulcerative colitis (ATLAS-UC trial) – The drug met its primary endpoint for clinical remission, positioning it as a potential blockbuster in the high-growth IBD market and signaling a successful strategic pivot beyond oncology.
• FDA approval of LIPFENDRA, the first oral PCSK9 inhibitor – This first-in-class therapy offers a patient-friendly alternative in cardiometabolic health, delivering a transformative diversification play and unlocking long-term commercial potential beyond Merck’s oncology-centric past.
• Summit Therapeutics reports transformative Phase III data for ivonescimab, showing superior overall survival vs. Keytruda in NSCLC with high PD-L1 expression – This is a direct challenge to Keytruda’s dominance and threatens to erode Merck’s core revenue stream if global approvals follow.